Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro

Monique Hinchcliff, Chiang Ching Huang, Wataru Ishida, Feng Fang, Jungwha Lee, Nadereh Jafari, Mark Wilkes, Swati Bhattacharyya, Edward B Leof, John Varga

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: Systemic sclerosis (SSc) is a heterogeneous multifactorial disease dominated by progressive skin and internal organ fibrosis that is driven in part by Transforming Growth Factorbeta (TGF-β). An important downstream target of TGF-β is the Abelson (c-Abl) tyrosine kinase, and its inhibition by imatinib mesylate (Gleevec) attenuates fibrosis in mice. Here we examined the effect of c-Abl activation and blockade in explanted healthy control and SSc fibroblasts. Methods: Skin biopsies and explanted fibroblasts from healthy subjects and patients with SSc were studied. Changes in genome-wide expression patterns in imatinib-treated control and SSc fibroblasts were analysed by DNA microarray. Results: Treatment of control fibroblasts with TGF-β resulted in activation of c-Abl and stimulation of fibrotic gene expression that was prevented by imatinib. Moreover, imatinib reduced basal collagen gene expression in SSc but not control fibroblasts. No significant differences in tissue levels of c- Abl and phospho-c-Abl were detected between SSc and control skin biopsies. In vitro, imatinib induced dramatic changes in the expression of genes involved in fibrosis, cardiovascular disease, inflammation, and lipid and cholesterol metabolism. Remarkably, of the 587-imatinib-responsive genes, 91% showed significant change in SSc fibroblasts, but only 12% in control fibroblasts. Conclusion: c-Abl plays a key role in fibrotic responses. Imatinib treatment results in dramatic changes in gene expression in SSc fibroblasts but has only modest effects in control fibroblasts. These data provide novel insights into the mechanisms underlying the antifibrotic effect of imatinib in SSc.

Original languageEnglish (US)
JournalClinical and Experimental Rheumatology
Volume30
Issue numberSUPPL.71
StatePublished - May 2012

Fingerprint

Systemic Scleroderma
Fibroblasts
Genome
Gene Expression
Fibrosis
Skin
Growth
Biopsy
In Vitro Techniques
Imatinib Mesylate
Oligonucleotide Array Sequence Analysis
Lipid Metabolism
Protein-Tyrosine Kinases
Healthy Volunteers
Cardiovascular Diseases
Collagen
Cholesterol
Inflammation
Therapeutics

Keywords

  • DNA microarray
  • Imatinib mesylate
  • Proto-oncogene proteins c-Abl
  • Systemic scleroderma

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Hinchcliff, M., Huang, C. C., Ishida, W., Fang, F., Lee, J., Jafari, N., ... Varga, J. (2012). Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro. Clinical and Experimental Rheumatology, 30(SUPPL.71).

Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro. / Hinchcliff, Monique; Huang, Chiang Ching; Ishida, Wataru; Fang, Feng; Lee, Jungwha; Jafari, Nadereh; Wilkes, Mark; Bhattacharyya, Swati; Leof, Edward B; Varga, John.

In: Clinical and Experimental Rheumatology, Vol. 30, No. SUPPL.71, 05.2012.

Research output: Contribution to journalArticle

Hinchcliff, M, Huang, CC, Ishida, W, Fang, F, Lee, J, Jafari, N, Wilkes, M, Bhattacharyya, S, Leof, EB & Varga, J 2012, 'Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro', Clinical and Experimental Rheumatology, vol. 30, no. SUPPL.71.
Hinchcliff, Monique ; Huang, Chiang Ching ; Ishida, Wataru ; Fang, Feng ; Lee, Jungwha ; Jafari, Nadereh ; Wilkes, Mark ; Bhattacharyya, Swati ; Leof, Edward B ; Varga, John. / Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro. In: Clinical and Experimental Rheumatology. 2012 ; Vol. 30, No. SUPPL.71.
@article{ee8f59b145224ab8942ef761146b3486,
title = "Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro",
abstract = "Objective: Systemic sclerosis (SSc) is a heterogeneous multifactorial disease dominated by progressive skin and internal organ fibrosis that is driven in part by Transforming Growth Factorbeta (TGF-β). An important downstream target of TGF-β is the Abelson (c-Abl) tyrosine kinase, and its inhibition by imatinib mesylate (Gleevec) attenuates fibrosis in mice. Here we examined the effect of c-Abl activation and blockade in explanted healthy control and SSc fibroblasts. Methods: Skin biopsies and explanted fibroblasts from healthy subjects and patients with SSc were studied. Changes in genome-wide expression patterns in imatinib-treated control and SSc fibroblasts were analysed by DNA microarray. Results: Treatment of control fibroblasts with TGF-β resulted in activation of c-Abl and stimulation of fibrotic gene expression that was prevented by imatinib. Moreover, imatinib reduced basal collagen gene expression in SSc but not control fibroblasts. No significant differences in tissue levels of c- Abl and phospho-c-Abl were detected between SSc and control skin biopsies. In vitro, imatinib induced dramatic changes in the expression of genes involved in fibrosis, cardiovascular disease, inflammation, and lipid and cholesterol metabolism. Remarkably, of the 587-imatinib-responsive genes, 91{\%} showed significant change in SSc fibroblasts, but only 12{\%} in control fibroblasts. Conclusion: c-Abl plays a key role in fibrotic responses. Imatinib treatment results in dramatic changes in gene expression in SSc fibroblasts but has only modest effects in control fibroblasts. These data provide novel insights into the mechanisms underlying the antifibrotic effect of imatinib in SSc.",
keywords = "DNA microarray, Imatinib mesylate, Proto-oncogene proteins c-Abl, Systemic scleroderma",
author = "Monique Hinchcliff and Huang, {Chiang Ching} and Wataru Ishida and Feng Fang and Jungwha Lee and Nadereh Jafari and Mark Wilkes and Swati Bhattacharyya and Leof, {Edward B} and John Varga",
year = "2012",
month = "5",
language = "English (US)",
volume = "30",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "SUPPL.71",

}

TY - JOUR

T1 - Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro

AU - Hinchcliff, Monique

AU - Huang, Chiang Ching

AU - Ishida, Wataru

AU - Fang, Feng

AU - Lee, Jungwha

AU - Jafari, Nadereh

AU - Wilkes, Mark

AU - Bhattacharyya, Swati

AU - Leof, Edward B

AU - Varga, John

PY - 2012/5

Y1 - 2012/5

N2 - Objective: Systemic sclerosis (SSc) is a heterogeneous multifactorial disease dominated by progressive skin and internal organ fibrosis that is driven in part by Transforming Growth Factorbeta (TGF-β). An important downstream target of TGF-β is the Abelson (c-Abl) tyrosine kinase, and its inhibition by imatinib mesylate (Gleevec) attenuates fibrosis in mice. Here we examined the effect of c-Abl activation and blockade in explanted healthy control and SSc fibroblasts. Methods: Skin biopsies and explanted fibroblasts from healthy subjects and patients with SSc were studied. Changes in genome-wide expression patterns in imatinib-treated control and SSc fibroblasts were analysed by DNA microarray. Results: Treatment of control fibroblasts with TGF-β resulted in activation of c-Abl and stimulation of fibrotic gene expression that was prevented by imatinib. Moreover, imatinib reduced basal collagen gene expression in SSc but not control fibroblasts. No significant differences in tissue levels of c- Abl and phospho-c-Abl were detected between SSc and control skin biopsies. In vitro, imatinib induced dramatic changes in the expression of genes involved in fibrosis, cardiovascular disease, inflammation, and lipid and cholesterol metabolism. Remarkably, of the 587-imatinib-responsive genes, 91% showed significant change in SSc fibroblasts, but only 12% in control fibroblasts. Conclusion: c-Abl plays a key role in fibrotic responses. Imatinib treatment results in dramatic changes in gene expression in SSc fibroblasts but has only modest effects in control fibroblasts. These data provide novel insights into the mechanisms underlying the antifibrotic effect of imatinib in SSc.

AB - Objective: Systemic sclerosis (SSc) is a heterogeneous multifactorial disease dominated by progressive skin and internal organ fibrosis that is driven in part by Transforming Growth Factorbeta (TGF-β). An important downstream target of TGF-β is the Abelson (c-Abl) tyrosine kinase, and its inhibition by imatinib mesylate (Gleevec) attenuates fibrosis in mice. Here we examined the effect of c-Abl activation and blockade in explanted healthy control and SSc fibroblasts. Methods: Skin biopsies and explanted fibroblasts from healthy subjects and patients with SSc were studied. Changes in genome-wide expression patterns in imatinib-treated control and SSc fibroblasts were analysed by DNA microarray. Results: Treatment of control fibroblasts with TGF-β resulted in activation of c-Abl and stimulation of fibrotic gene expression that was prevented by imatinib. Moreover, imatinib reduced basal collagen gene expression in SSc but not control fibroblasts. No significant differences in tissue levels of c- Abl and phospho-c-Abl were detected between SSc and control skin biopsies. In vitro, imatinib induced dramatic changes in the expression of genes involved in fibrosis, cardiovascular disease, inflammation, and lipid and cholesterol metabolism. Remarkably, of the 587-imatinib-responsive genes, 91% showed significant change in SSc fibroblasts, but only 12% in control fibroblasts. Conclusion: c-Abl plays a key role in fibrotic responses. Imatinib treatment results in dramatic changes in gene expression in SSc fibroblasts but has only modest effects in control fibroblasts. These data provide novel insights into the mechanisms underlying the antifibrotic effect of imatinib in SSc.

KW - DNA microarray

KW - Imatinib mesylate

KW - Proto-oncogene proteins c-Abl

KW - Systemic scleroderma

UR - http://www.scopus.com/inward/record.url?scp=84867379154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867379154&partnerID=8YFLogxK

M3 - Article

C2 - 22691216

AN - SCOPUS:84867379154

VL - 30

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - SUPPL.71

ER -